雷利度胺治疗自体造血干细胞移植后复发套细胞淋巴瘤一例并文献复习

Lenalidomide for the patient with mantle cell lymphoma who relapsed after autologous hematopoietic stem cell transplantation: a case report and review of the literature

目的评价雷利度胺对自体造血干细胞移植(AHSCT)后复发难治性套细胞淋巴瘤的疗效。方法回顾性分析浙江中医药大学附属第一医院血液科收治的1例行AHSCT后2次复发套细胞淋巴瘤患者的临床资料和治疗经过。先后应用雷利度胺联合地塞米松以及雷利度胺联合COD方案(环磷酰胺、长春瑞滨和地塞米松)治疗,并结合文献进行分析讨论。结果患者经以雷利度胺为主方案治疗后,疾病再次获得完全缓解,截至2015年11月初已经随访6个月,疾病未见复发。结论雷利度胺对复发难治性套细胞淋巴瘤有良好的治疗效果,可以作为AHSCT后复发套细胞淋巴瘤患者有效的治疗手段。

Objective To evaluate the efficiency of Lenalidomide in relapsed/refractory mantle cell lymphoma. Methods A retrospective study was performed on 1 patient with relapsed mantle cell lymphoma after autologous hematopoietic stem cell transplantation （AHSCT）. The patient was successively treated with Lenalidomide in combination with dexamcthasone and COD （cyclophosphamide, vinorelbine and dexamethasone） respectively, and then discussed with literature. Results The patient achieved complete remission after Lenalidomide-hased therapy, and now has been followed up for 6 months, and no recurrence of disease was found. Conclusions Lenalidomide has a good therapeutic effect for the relapsed/refractory mantle cell lymphoma, which can serve as an effective mean for relapsed mantle cell lymphoma after AHSCT.